[Featured Stock] Dongwha Pharm Applies for Phase 2 Clinical Trial of Antiviral COVID-19 Treatment... 'Strong Performance'
[Asia Economy Reporter Yoo Hyun-seok] Dongwha Pharm is showing strength. It appears that the news of applying for Phase 2 clinical trials of the novel coronavirus disease (COVID-19) treatment DW2008S, which has antiviral efficacy, has had an impact.
As of 9:09 AM on the 19th, Dongwha Pharm was trading at 22,650 KRW, up 2.95% (650 KRW) compared to the previous trading day.
On the same day, Dongwha Pharm announced that it had applied to the Ministry of Food and Drug Safety for Phase 2 clinical trials of the COVID-19 treatment DW2008S.
Animal efficacy tests on ferrets conducted at Chungbuk National University confirmed the antiviral efficacy of DW2008S. The DW2008S treatment group showed significant virus suppression efficacy from the second day, the early stage of infection, compared to the infected control group. Continuous effects were observed throughout the test period.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- "I Will Give Them a Chance for Self-Examination": Chinese Scientific Community Shaken by Influencer's Preemptive Whistleblowing
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Imase, head of Dongwha Pharm's research institute, stated, "It took a long time to obtain the animal efficacy test results, but as expected, DW2008S showed positive antiviral efficacy." He added, "Dongwha Pharm will continue to do its best to contribute to ending the global COVID-19 crisis through new drug development."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
